XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENTS
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
SEGMENTS

4. SEGMENTS

 

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision–making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision-maker is the CEO. The Company operates in and reports four business segments: real estate, digital transformation technology, biohealth, and other business activities. The Company’s reportable segments are determined based on the services they perform and the products they sell, not on the geographic area in which they operate. The Company’s chief operating decision maker evaluates segment performance based on segment revenue. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative activities which are not allocable to the four reportable segments.

 

The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the six months ended June 30, 2023 and 2022:

 

   Real Estate   Digital Transformation Technology   Biohealth Business   Other   Total 
                     
Six Months Ended on June 30, 2023                         
Revenue  $19,515,728   $28,074   $12,786   $524,196   $20,080,784 
Cost of Sales   (12,168,470)   (9,139)   (109,657)   (140,508)   (12,427,774)
Gross Margin   7,347,258    18,935    (96,871)   383,688    7,653,010 
Operating Expenses   (992,201)   (202,430)   (477,917)   (2,960,696)   (4,633,244)
Operating Loss   6,355,057    (183,495)   (574,788)   (2,577,008)   3,019,766 
Other Income (Expense)   215,306    (1,091,514)   835,888    (13,116,034)   (13,156,354)
Net Loss Before Income Tax  $6,570,363   $(1,275,009)  $261,100   $(15,693,042)  $(10,136,588)

 

    Real Estate     Digital Transformation Technology     Biohealth Business     Other     Total  
                               
Six Months Ended on June 30, 2022                                        
Revenue   $ 1,924,916     $ 7,701     $ 749,693     $ 196,267     $ 2,878,577  
Cost of Sales     (1,625,942 )     (2,792 )     (11,985 )     (24,508 )     (1,665,227 )
Gross Margin     298,974       4,909       737,708       171,759       1,213,350  
Operating Expenses     (1,320,957 )     (159,976 )     (910,246 )     (2,129,974 )     (4,521,153 )
Operating (Loss) Income     (1,021,983 )     (155,067 )     (172,538 )     (1,958,215 )     (3,307,803 )
Other Expense     209       (764,968 )     (3,039,097 )     (10,579,541 )     (14,383,397 )
Net Loss Before Income Tax   $ (1,021,774 )   $ (920,035 )   $ (3,211,635 )   $ (12,537,756 )   $ (17,691,200 )
                                         
June 30, 2023                                        
Cash and Restricted Cash   $ 2,209,538     $ 461,704     $ 991,986     $ 25,828,907     $ 29,492,135  
Total Assets     61,091,436       3,516,613       5,136,085       98,697,677       168,441,811  
                                         
December 31, 2022                                        
Cash and Restricted Cash   $ 2,592,577     $ 514,260     $ 1,338,404     $ 14,076,662     $ 18,521,903  
Total Assets     57,951,324       3,184,416       4,861,615       87,492,981       153,490,336